

EDWARDS LIFESCIENCES CORPORATION
Unaudited Consolidated Statements of Operations

(in millions, except per share data)	Three Months Ended		Nine Months Ended	
	September 30, 2008	2007	September 30, 2008	2007
Net sales	\$303.6	\$261.4	\$928.0	\$798.1
Cost of goods sold	104.9	90.7	320.8	278.6
Gross profit	198.7	170.7	607.2	519.5
Selling, general and administrative expenses	119.3	103.2	360.4	303.5
Research and development expenses	35.1	30.9	103.4	88.8
Special (gains) charges, net	-	(2.5)	9.3	(2.5)
Interest (income) expense, net	(0.4)	0.4	0.4	1.0
Other expense (income), net	1.1	(0.1)	3.3	(1.5)
Income before provision for income taxes	43.6	38.8	130.4	130.2
Provision for income taxes	10.7	9.7	39.6	33.0
Net income	\$32.9	\$29.1	\$90.8	\$97.2

Earnings per share:

Basic earnings per share	\$0.59	\$0.51	\$1.63	\$1.69
Diluted earnings per share	\$0.56	\$0.48	\$1.54	\$1.59

Weighted average common shares outstanding:

Basic	56.0	57.1	55.8	57.5
Diluted	59.0	62.4	60.1	63.0

Operating Statistics

As a percentage of net sales:				
Gross profit	65.4%	65.3%	65.4%	65.1%
Selling, general and administrative expenses	39.3%	39.5%	38.8%	38.0%
Research and development expenses	11.6%	11.8%	11.1%	11.1%
Income before provision for income taxes	14.4%	14.8%	14.1%	16.3%
Net income	10.8%	11.1%	9.8%	12.2%
Effective tax rate	24.5%	25.0%	30.4%	25.3%

Computation of Diluted Earnings per Share

Net income	\$32.9	\$29.1	\$90.8	\$97.2
Adjustment for convertible debt interest expense	-	1.0	1.7	3.0
Adjusted net income	\$32.9	\$30.1	\$92.5	\$100.2
Weighted average common shares outstanding used to calculate diluted earnings per share excluding convertible debt	59.0	59.7	58.5	60.3
Weighted average common shares outstanding for the convertible debt	-	2.7	1.6	2.7
Weighted average common shares outstanding used to calculate diluted earnings per share including the convertible debt	59.0	62.4	60.1	63.0
Diluted earnings per share including the convertible debt	\$0.56	\$0.48	\$1.54	\$1.59

Note: Numbers may not foot due to rounding

EDWARDS LIFESCIENCES CORPORATION**Unaudited Balance Sheets**

(in millions)

	<u>September 30, 2008</u>	<u>December 31, 2007</u>
ASSETS		
Current assets		
Cash and cash equivalents	\$202.4	\$141.8
Short-term investments	12.1	49.4
Accounts and other receivables, net	213.6	145.3
Inventories, net	143.8	152.6
Deferred income taxes	28.0	30.2
Prepaid expenses	37.8	25.4
Other current assets	38.6	37.0
Total current assets	<u>676.3</u>	<u>581.7</u>
Property, plant and equipment, net	224.0	228.2
Goodwill	315.7	350.3
Other intangible assets, net	107.9	122.5
Investments in unconsolidated affiliates	20.3	34.3
Deferred income taxes	19.7	13.8
Other assets	17.3	14.3
Total assets	<u><u>\$1,381.2</u></u>	<u><u>\$1,345.1</u></u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities	\$229.9	\$225.4
Convertible debt	-	150.0
Total current liabilities	<u>229.9</u>	<u>375.4</u>
Long-term debt	<u>202.8</u>	<u>61.7</u>
Other long-term liabilities	<u>74.0</u>	<u>73.0</u>
Stockholders' equity		
Common stock	73.3	68.6
Additional contributed capital	912.6	680.6
Retained earnings	639.4	548.6
Accumulated other comprehensive income	5.0	7.5
Common stock in treasury, at cost	(755.8)	(470.3)
Total stockholders' equity	<u>874.5</u>	<u>835.0</u>
Total liabilities and stockholders' equity	<u><u>\$1,381.2</u></u>	<u><u>\$1,345.1</u></u>

EDWARDS LIFESCIENCES CORPORATION

Non-GAAP Financial Information

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP financial measures that exclude certain items, such as special charges and gains, results of discontinued or newly acquired products, and fluctuations in exchange rates. Management does not consider the excluded items part of day-to-day business or reflective of the core operational activities of the Company as they result from transactions outside the ordinary course of business.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. Certain guidance is provided only on a non-GAAP basis that excludes special items and foreign exchange fluctuations due to the inherent difficulty in forecasting such items. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the Company's core operating results and trends for the periods presented.

Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, nor superior to, the corresponding measures calculated in accordance with GAAP.

The items described below are excluded from the GAAP financial results in the reconciliations that follow:

Special (Gains) Charges, net - The Company incurred certain special charges and gains in 2008 and 2007 related to the following:

- 1) *Loss on sale of product line*: \$8.1 million net loss on the sale of the LifeStent product line in the first quarter of 2008;
- 2) *Litigation settlement*: \$2.1 million charge for a litigation settlement;
- 3) *Realignment expenses, net*: \$1.3 million charge for executive severance in the first quarter of 2008 associated with the Company's business realignment, offset by a \$1.4 million gain from the reversal of previously accrued severance costs from the fourth quarter of 2007 related to the sale of the LifeStent product line; \$0.8 million gain in the second quarter of 2008 from the reversal of previously accrued severance costs in the fourth quarter of 2007 related to the global reduction in workforce.
- 4) *Gain on estimated insurance settlement*: \$2.5 million gain in the third quarter of 2007 from the estimated insurance settlement from a fire that destroyed certain inventory held at a third party warehouse in Brazil. In the fourth quarter of 2007, the Company reversed this gain as it will be recognized upon settlement.

Given the magnitude and unusual nature of these special charges and gains relative to the operating results for the periods presented, these items have been excluded from non-GAAP net income.

Results of Discontinued or Newly Acquired Products – The Company has discontinued or acquired certain products during the periods presented. As discontinued products do not have a continuing contribution to operations, management believes that excluding such items from the Company's sales growth provides investors with a means of evaluating the Company's on-going operations. As the impact of acquired product sales are only reflected prospectively, management believes including such items in the prior periods on a pro forma basis provides for greater comparability of the results of operations. In light of the significance of the impact these products had on the sales growth of the Company, the sales results of these products have been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."

Foreign Exchange - Fluctuation in exchange rates impacts the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of foreign exchange rate fluctuations from its sales growth provides investors a more meaningful comparison to historical financial results. The impact of foreign exchange rate fluctuations has been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."

EDWARDS LIFESCIENCES CORPORATION
Reconciliation of GAAP to Non-GAAP Financial Information

(in millions, except per share data)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
GAAP net income	\$32.9	\$29.1	\$90.8	\$97.2
Reconciling items:				
Special (gains) charges, net				
1) Loss on sale of product line	-	-	8.1	-
2) Litigation settlement	-	-	2.1	-
3) Realignment expenses, net	-	-	(0.9)	-
4) Gain on estimated insurance settlement	-	(2.5)	-	(2.5)
Total special (gains) charges, net	-	(2.5)	9.3	(2.5)
Provision for income taxes				
Tax effect on non-GAAP adjustments (A)	-	1.0	5.0	1.0
Total provision for income taxes, net	-	1.0	5.0	1.0
Non-GAAP net income	\$32.9	\$27.6	\$105.1	\$95.7
Non-GAAP earnings per share:				
Basic non-GAAP earnings per share	\$0.59	\$0.48	\$1.88	\$1.66
Diluted non-GAAP earnings per share (B)	\$0.56	\$0.46	\$1.78	\$1.57
Non-GAAP weighted average shares outstanding:				
Basic	56.0	57.1	55.8	57.5
Diluted	59.0	62.4	60.1	63.0

Notes 1 - 4: See description of Special (Gains) Charges, net on the previous page.

(A) The tax effect on non-GAAP adjustments is calculated using the relevant tax jurisdictions' statutory tax rates.

(B) Diluted non-GAAP earnings per share is calculated by adding back to net income \$1.7 million for the nine month period in interest expense related to the convertible debt, then dividing by the weighted average diluted shares outstanding.

Note: Numbers may not calculate due to rounding

EDWARDS LIFESCIENCES CORPORATION
Unaudited Reconciliation of Sales by Product Line and Region
(in millions)

Sales by Product Line (QTD)	3Q 2008	3Q 2007	Change	GAAP Growth Rate	2008 Adjusted		2007 Adjusted			Underlying Growth Rate *
					Discontinued Product Line Impact	3Q 2008 Underlying Sales	Discontinued/Acquired Product Line Impact	FX Impact	3Q 2007 Underlying Sales	
Heart Valve Therapy	\$ 148.4	\$ 122.8	\$ 25.6	20.8%	\$ (0.2)	\$ 148.2	\$ (1.2)	\$ 5.4	\$ 127.0	16.7%
Critical Care	110.3	96.5	13.8	14.3%	-	110.3	-	4.5	101.0	9.2%
Cardiac Surgery Systems	21.4	13.8	7.6	55.1%	-	21.4	4.9	0.7	19.4	10.1%
Vascular	23.5	22.4	1.1	4.9%	(9.3)	14.2	(8.4)	0.8	14.8	(4.0%)
Other Distributed Products	-	5.9	(5.9)	(100.0%)	-	-	(5.7)	(0.2)	-	-
Total Sales	\$ 303.6	\$ 261.4	\$ 42.2	16.1%	\$ (9.5)	\$ 294.1	\$ (10.4)	\$ 11.2	\$ 262.2	12.2%

Sales by Product Line (YTD)	YTD 3Q 2008	YTD 3Q 2007	Change	GAAP Growth Rate	2008 Adjusted		2007 Adjusted			Underlying Growth Rate *
					Discontinued Product Line Impact	YTD 2008 Underlying Sales	Discontinued/Acquired Product Line Impact	FX Impact	YTD 2007 Underlying Sales	
Heart Valve Therapy	\$ 457.7	\$ 383.6	\$ 74.1	19.3%	\$ (0.2)	\$ 457.5	\$ (5.1)	\$ 21.2	\$ 399.7	14.5%
Critical Care	333.6	284.8	48.8	17.1%	(0.6)	333.0	-	17.3	302.1	10.2%
Cardiac Surgery Systems	66.3	45.8	20.5	44.8%	(0.2)	66.1	11.9	2.5	60.2	9.8%
Vascular	70.4	64.9	5.5	8.5%	(27.0)	43.4	(22.6)	2.8	45.1	(3.8%)
Other Distributed Products	-	19.0	(19.0)	(100.0%)	-	-	(18.9)	(0.1)	-	-
Total Sales	\$ 928.0	\$ 798.1	\$ 129.9	16.3%	\$ (28.0)	\$ 900.0	\$ (34.7)	\$ 43.7	\$ 807.1	11.5%

Sales by Region (QTD)	3Q 2008	3Q 2007	Change	GAAP Growth Rate
United States	\$ 135.6	\$ 118.1	\$ 17.5	14.8%
Europe	89.6	71.0	18.6	26.2%
Japan	42.4	39.9	2.5	6.3%
Rest of World	36.0	32.4	3.6	11.1%
International	168.0	143.3	24.7	17.2%
Total	\$ 303.6	\$ 261.4	\$ 42.2	16.1%

Sales by Region (YTD)	YTD 3Q 2008	YTD 3Q 2007	Change	GAAP Growth Rate
United States	\$ 410.8	\$ 362.7	\$ 48.1	13.3%
Europe	286.5	223.4	63.1	28.2%
Japan	125.7	120.8	4.9	4.1%
Rest of World	105.0	91.2	13.8	15.1%
International	517.2	435.4	81.8	18.8%
Total	\$ 928.0	\$ 798.1	\$ 129.9	16.3%

* Numbers may not calculate due to rounding.